福瑞股份涨2.05%，成交额8.74亿元，主力资金净流出3704.53万元

Core Viewpoint - Furuya Co., Ltd. has shown significant stock price growth in 2023, with a year-to-date increase of 177.74% and a recent surge of 34.83% over the past five trading days [1] Financial Performance - For the first half of 2025, Furuya Co., Ltd. achieved operating revenue of 713 million yuan, representing a year-on-year growth of 11.02%. However, the net profit attributable to shareholders decreased by 31.09% to 51.93 million yuan [2] - The company has distributed a total of 246 million yuan in dividends since its A-share listing, with 52.61 million yuan distributed over the past three years [3] Stock Market Activity - As of September 17, 2023, Furuya Co., Ltd.'s stock price was 87.60 yuan per share, with a market capitalization of 23.212 billion yuan. The stock experienced a trading volume of 874 million yuan and a turnover rate of 4.34% [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on September 15, 2023, where it recorded a net purchase of 74.25 million yuan [1] Shareholder Information - As of August 29, 2023, Furuya Co., Ltd. had 25,600 shareholders, an increase of 6.91% from the previous period. The average number of circulating shares per shareholder was 9,108, a decrease of 6.47% [2] - The top ten circulating shareholders include notable funds such as Huabao Zhongzheng Medical ETF and Ruiyuan Growth Value Mixed A, with varying changes in their holdings [3] Business Overview - Furuya Co., Ltd. specializes in the production and sales of pharmaceuticals in the liver disease sector, as well as the research and sales of medical instruments and services. The revenue composition is as follows: 67.57% from equipment and technology, 27.47% from pharmaceuticals, 4.30% from medical services, and 0.65% from other sources [1]